Fazer um exame de títulos de anticorpos ou um reforço da vacina tríplice viral (MMR) na idade adulta durante o ressurgimento do sarampo de 2025, ou dispensar?
Se você agir
Fazer titulação ou reforço da vacina tríplice viral em adulto
Sem medição direta
Se você não agir
Dispensar a titulação/reforço e confiar na imunidade da infância
6,0%
Pelo menos um número é uma estimativa indireta, não uma taxa de arrependimento medida. Abaixo explicamos como cada número foi obtido.
Saúde
Última revisão 2026-06-13
Qualidade das evidências 4.1/5
Pontuação de revisão em oito dimensões segundo a
grelha de qualidade
. Cada dimensão pontuada de 1 a 5.
D1 Verificação das fontes
5/5
D2 Autoridade e independência das fontes
5/5
D3 Precisão da taxa de arrependimento
3/5
D4 Comparabilidade das fontes
3/5
D5 Padrão de Gilovich
4/5
D6 Qualidade da prosa
4/5
D7 Completude das ressalvas
4/5
D8 Qualidade da amostra
5/5
Média4.1/5
Dados indiretos: para esta decisão, pelo menos um número vem de uma medida indireta, como desfechos, satisfação ou intenção, ou de uma estimativa editorial, e não de uma pesquisa direta sobre arrependimento. As notas de cada lado, abaixo, explicam como cada número foi obtido.
Se você agir
Fazer titulação ou reforço da vacina tríplice viral em adulto
Sem medição direta
Nenhuma fonte indica um número para este lado, por isso não mostramos nenhum.
US adults who seek an MMR titer or a precautionary MMR dose (1963-67 killed-vaccine cohort, healthcare personnel, immunocompromised contacts) during the 2025 resurgence
Per dose administered
Se você não agir
Dispensar a titulação/reforço e confiar na imunidade da infância
6,0%
~6% — proxy: share of a US healthcare-worker serosurvey lacking a measles immunity marker (seronegative + equivocal); an upper bound on who carries an immunity gap, not a measured regret rate
US adults in the named higher-risk cohorts (1963-67 killed-vaccine recipients, healthcare personnel, immunocompromised) who skip serologic check or revaccination during the 2025 resurgence
Cross-sectional immunity gap during the 2025 resurgence
Número de cada escolha (a medida está indicada na página)
Fazer titulação ou reforço da vacina tríplice viral em adultoDispensar a titulação/reforço e confiar na imunidade da infância
Sem medição direta6,0%
Decisões relacionadas
Decisões semanticamente semelhantes — mesmo terreno, compromissos diferentes.
No survey asks adults whether they regret getting, or skipping, a measles booster during the 2025 resurgence. This pair is a proxy. The action side is anchored on the probability of a serious adverse event from the shot itself, and the inaction side on the share of the relevant cohort that carries no measurable measles immunity. Neither number is a regret rate; both are stand-ins.
Anaphylaxis after an MMR-containing vaccine was reported to VAERS at 0.6 per million doses over 1990 to 2016, and the CDC’s Vaccine Information Statement describes a serious reaction as a “very remote chance.” The common outcomes are a sore arm, a brief fever and a mild rash.
The inaction side is where the cohorts in the question matter. A US healthcare-worker serosurvey found 4% seronegative and 2% equivocal for measles IgG — a roughly 6% immunity gap — and a 2025 meta-analysis of 23,236 vaccinated people pooled seropositivity at 87.8%, falling to 84.3% among single-dose recipients. The 1963-67 killed-vaccine cohort is a separate, smaller group that ACIP explicitly tells to revaccinate, because the inactivated product conferred little durable protection. The catch is that an immunity gap is not the same as realized regret: with 2,289 confirmed US cases in 2025 against a population of roughly 340 million, the national attack rate stayed near 0.0007%, so most seronegative adults were never exposed at all. What gives the gap its weight is the severity tail — 11% of 2025 cases were hospitalized and there were deaths — so the rare intersection of “no immunity” and “exposed” is consequential.
Fontes: acção
Registro de evidências
Cada número abaixo é o que cada fonte relatou, com a citação literal em que nos baseamos e como chegamos ao nosso valor. Clique em qualquer link para verificar diretamente.
1/2 fontes verificadas de forma independente palavra por palavra em relação à fonte citada
[1]Journal of Allergy and Clinical Immunology / NCBI PMC — Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990–2016
Verificado
Revisado por pares
MMR-containing vaccine anaphylaxis reporting rate of 0.6 per 1 million doses distributed (overall vaccine rate 1.3 per million).
Trecho
“The estimated rate of anaphylaxis reported to VAERS during 1990 to 2016 after MMR was 0.6 per 1 million doses distributed.”
Dados da fonte de
2019-01-01
Acessado
2026-06-13
Verificação
Trecho obtido novamente de forma independente e confirmado palavra por palavra em relação à fonte citada durante nossa auditoria de fundamentação.
Cálculo
Anaphylaxis is the canonical serious adverse event of MMR. 0.6 per 1,000,000 doses = 6e-7. The action regret rate is set conservatively above that floor (1e-5) to absorb other rare serious events (febrile seizure, transient thrombocytopenia) the VIS lists. The dominant 'downside' of acting for an already-immune adult is a redundant dose, which yields peace of mind rather than regret, so it is not counted as regret. This is the matched-severity proxy: action's regret-worthy outcome is a serious AE, not 'the shot turned out unnecessary'.
[2]U.S. Centers for Disease Control and Prevention — MMR Vaccine Information Statement (VIS)
Relatório governamental
Serious adverse events from MMR are characterized as a very remote chance; common effects are minor (sore arm, fever, mild rash).
Trecho
“As with any medicine, there is a very remote chance of a vaccine causing a severe allergic reaction, other serious injury, or death.”
Dados da fonte de
2025-01-31
Acessado
2026-06-13
Cálculo
Qualitative confirmation that the action side's serious downside is 'very remote.' Establishes that the regret-worthy outcome of acting is rare and severe (an AE), distinct from the common, non-regret outcome of a redundant-but-protective dose. No numeric rate on this page; the numeric anchor is PMC6580415.
Fontes: inacção
Registro de evidências
Cada número abaixo é o que cada fonte relatou, com a citação literal em que nos baseamos e como chegamos ao nosso valor. Clique em qualquer link para verificar diretamente.
3/6 fontes verificadas de forma independente palavra por palavra em relação à fonte citada
[1]Infection Control and Hospital Epidemiology (PubMed) — Measles immunity in a population of healthcare workers
Verificado
Revisado por pares
Among 2,473 US healthcare workers tested for anti-measles IgG, 4% were seronegative and 2% equivocal — a ~6% immunity gap.
Trecho
“Ninety-three workers (4%) were seronegative, and 56 (2%) were equivocal.”
Dados da fonte de
1994-01-01
Acessado
2026-06-13
Verificação
Trecho obtido novamente de forma independente e confirmado palavra por palavra em relação à fonte citada durante nossa auditoria de fundamentação.
Cálculo
Population-matched anchor: US healthcare workers, one of the named higher-risk cohorts. Seronegative (4%) + equivocal (2%) = 6% lacking a measles immunity marker → inaction proxy 0.06. This is an immunity-gap upper bound, not a realized-regret rate: most seronegative people are never exposed (2025 national attack rate ~ 2,289 / ~340M ~ 0.0007%). The proxy measures who is even eligible for potential regret if exposed.
[2]eClinicalMedicine (The Lancet Discovery Science) — Measles seropositivity in previously vaccinated individuals: a systematic review and meta-analysis
Revisado por pares
Pooled seropositivity among vaccinated individuals was 87.8% (so ~12.2% seronegative); single-dose recipients 84.3% seropositive (~15.7% seronegative), across 23,236 individuals from 10 countries.
Trecho
“Pooled seropositivity was 87·8% (95% CI, 83·9%–91·2%) across 23,236 vaccinated individuals”
Dados da fonte de
2025-01-01
Acessado
2026-06-13
Cálculo
Current (2025) pooled anchor confirming waning: ~12% of vaccinated adults are below seropositivity thresholds, rising to ~16% for single-dose recipients. Verified verbatim via Playwright (the Lancet page blocks plain fetching). Used to frame the spread; the 6% HCW figure is kept as the population-matched headline rather than the 12-16% pooled (mixed-country, assay-threshold) number to avoid overstating realized susceptibility.
[3]U.S. Centers for Disease Control and Prevention — Measles Vaccination for Specific Groups
Relatório governamental
ACIP recommends revaccinating recipients of killed/inactivated or unknown-type measles vaccine from 1963-1967; healthcare personnel without presumptive immunity need 2 doses.
Trecho
“The ACIP recommends re-vaccinating anyone who received measles vaccine of unknown type, inactivated measles vaccine, or further attenuated measles vaccine accompanied by immunoglobulin or high-titer measles immune globulin (no longer available in the United States) during these years with 1 or 2 doses.”
Dados da fonte de
2024-07-15
Acessado
2026-06-13
Cálculo
Establishes that the 1963-67 killed-vaccine cohort is functionally unprotected per ACIP and explicitly advised to revaccinate — the qualitative basis for why skipping carries downside for this cohort. This cohort is <5% of adults and overlaps the pre-1957 presumed-immune group, so it informs but does not set the numeric anchor.
[4]CDC MMWR / NCBI PMC — Measles Update — United States, January 1–April 17, 2025
Verificado
Relatório governamental
Of 800 confirmed 2025 cases through April 17, 96% were unvaccinated or unknown status, 11% hospitalized, 3 deaths.
Trecho
“Overall, 771 (96%) patients have been unvaccinated or had unknown vaccination status”
Dados da fonte de
2025-04-24
Acessado
2026-06-13
Verificação
Trecho obtido novamente de forma independente e confirmado palavra por palavra em relação à fonte citada durante nossa auditoria de fundamentação.
Cálculo
Establishes the severity tail that makes the immunity gap consequential: 11% of measles cases hospitalized, 3 deaths in the period, 96% of cases in the unvaccinated/unknown. The realized harm to someone in the immunity gap who is exposed is severe; this is what gives the inaction proxy its weight.
[5]U.S. Centers for Disease Control and Prevention — Measles Cases and Outbreaks — 2025 Data Summary
Verificado
Relatório governamental
“For the full year of 2025, a total of 2,289 confirmed* measles cases were reported in the United States.”
Dados da fonte de
2026-06-12
Acessado
2026-11-04
Verificação
Trecho obtido novamente de forma independente e confirmado palavra por palavra em relação à fonte citada durante nossa auditoria de fundamentação.
Cálculo
Sets the exposure backdrop: 2,289 cases / ~340M US population ~ 0.0007% national attack rate. This is why the 6% immunity-gap proxy is explicitly an upper bound on potential regret, not realized regret — exposure remained geographically concentrated and rare nationally even in 2025.
[6]The Texas Tribune — Texas measles victim's parents stand by decision to not vaccinate
Artigo de notícia
After their unvaccinated 6-year-old daughter died of measles in Gaines County, Texas in February 2025, the parents said in a recorded statement that the death did not change their opposition to the MMR vaccine.
Trecho
“"“We would absolutely not take the MMR,” the mother said in English, referring to the measles-mumps-rubella vaccination children typically receive before attending school. She said her stance on vaccination has not changed after her daughter’s death."
”
Dados da fonte de
2025-03-20
Acessado
2026-07-03
Cálculo
Illustrative real-world counterpoint, not a numeric input to the 0.06 inaction proxy: a parent's decision about a child's routine MMR dose amid a measles death is a different population and decision from the adult titer/booster question this entry covers, and one family's account is not a survey. Cited to support the body-text point that documented post-outbreak reactions do not uniformly run toward regretting non-vaccination.
Ressalvas
Proxy figures only: there is no direct "regret getting/skipping an MMR booster" survey; both rates are stand-ins. The inaction rate (6%) is the share of a US healthcare-worker serosurvey lacking an immunity marker (seronegative + equivocal), i.e. an upper bound on who is even eligible for regret, NOT a measured regret rate — most seronegative people are never exposed (2025 national attack rate ~0.0007%). The susceptibility spread is wide and assay-dependent: 6% (US HCW IgG), 12.2% (2025 pooled meta-analysis), up to ~37.6% in one Olmsted County, MN commercial-assay study whose high figure is largely a below-titer-threshold artifact (titer below cutoff does not equal susceptible, because anamnestic memory-B-cell immunity is not captured) and is therefore excluded from the anchor. The 1963-67 killed-vaccine cohort is <5% of adults and overlaps the pre-1957 presumed-immune group, so it is a qualitative ACIP-revaccinate flag rather than the numeric anchor. The action anaphylaxis figure (0.6/million) is a passive-surveillance VAERS reporting rate, not a measured incidence. The meta-analysis pools 10 countries, not US-only. CDC publishes immunity and case data, not regret; this entry should not be read as advice to get or skip a dose.